BIOLASE, Inc. announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists. The trial, led by an independent consultant, evaluated both the potential return on investment (ROI) and clinical adoption of BIOLASE's leading technology. The trial revealed unanimous doctor satisfaction with the performance and desire to recommend the purchase to others.

This represented the second trial performed by dentists at a dental service organization where all the participants who evaluated the laser also purchased the unit. The independent consultant and the dentists involved in the trial assessed that this advanced technology allows providers to do procedures they were not previously able to perform. This expanded capability helped keep more patients and the potential revenue associated with those patients within the practice and decreased referrals to specialists.

The Waterlase iPlus laser is a versatile tool that can be used for a variety of dental procedures, including tooth extractions, periodontal surgery, and cavity fillings. The laser is also FDA-approved for use in treating periodontal disease. After an evaluation of the potential ROI, all six dentists involved in the trial elected to purchase the laser and stated that they would recommend their colleagues do the same.